ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-PO621

Analysis of the Real-World Management of IgA Nephropathy (IgAN) Patients in Five European Countries

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Csomor, Philipp, CSL Vifor, Glattbrugg, Zurich, Switzerland
  • Hurtado, Tucker Bittel, Spherix Global Insights, Exton, Pennsylvania, United States
  • Dudzenski, Chris, Spherix Global Insights, Exton, Pennsylvania, United States
  • Santos, Lucy, CSL Vifor, Glattbrugg, Zurich, Switzerland

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Current treatment strategies focus on controlling blood pressure and minimising proteinuria. This study investigated the real-world management of IgAN in five European countries through a physician questionnaire and patient chart review.


From 21 Dec 2022 to 6 Feb 2023, physicians from France, Germany, Italy, Spain and the UK completed a questionnaire on IgAN management, and patient charts from their centres were analysed. Physicians had to have ≥50 CKD stage 1–4 patients under their management, including ≥4 IgAN patients not on dialysis. Patients had to be ≥12 years, diagnosed with IgAN, not be on dialysis and have an eGFR ≥15 mL/min/1.73m2.


Participating physicians (N=261) each saw a mean of 30 IgAN patients in the past year. Patients audited as part of the study (N=473) were mostly male (71%), 78% were Caucasian, mean age was 47 years and 57% were in CKD stage 3. The mean time since referral to their current physician was 4.2 years. Proteinuria was >1 g/day in 66% of patients at referral and in 50% of patients at the current assessment (N=403 with both referral and current values). This was despite 92% of patients currently taking an ACE inhibitor and/or ARB, 43% taking an SGLT2 inhibitor and 16% taking a steroid. Physicians considered rate of eGFR decline to be moderate in 19% and fast in 6% of patients. However, among patients with eGFR values over 2 years (N=293), rate of eGFR decline was 3 mL/year in 12%, 4–5 mL/year in 16% and ≥6 mL/year in 19% of patients. Relapse occurred at least once in 54% of patients; steroid therapy was used to control the most recent relapse episode in 60% of patients. Most physicians (78%) agreed that they would prefer to administer therapies specifically approved for IgAN and 66% agreed that there is a lack of non-immunosuppressive treatments for IgAN.


Many patients with IgAN continue to have persistent proteinuria despite ACE inhibitor/ARB treatment, and progressive disease is common. Overall, this study indicates that there is a need for more effective treatment strategies to reduce proteinuria and disease progression in patients with IgAN.


  • Commercial Support – CSL Vifor